Výsledky vyhledávání - "Eva Řezníčková"

Akademický článek

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

Autor: Kristina Breitenecker, Viola Hedrich, Franziska Pupp, Doris Chen, Eva Řezníčková, Gregor Ortmayr, Heidemarie Huber, Gerhard Weber, Lorenz Balcar, Matthias Pinter, Wolfgang Mikulits

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

IntroductionHepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in seco

Externí odkaz: https://doaj.org/article/c7d00e5156d647469e16c383d6cf5ad0

Zobrazit plný text záznamu

Akademický článek

Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7

Autor: Markéta Kovalová, Libor Havlíček, Stefan Djukic, Jana Škerlová, Miroslav Peřina, Tomáš Pospíšil, Eva Řezníčková, Pavlína Řezáčová, Radek Jorda, Vladimír Kryštof

Publikováno v: Biomedicine & Pharmacotherapy, Vol 161, Iss , Pp 114492- (2023)

Targeting cyclin-dependent kinase 7 (CDK7) provides an interesting therapeutic option in cancer therapy because this kinase participates in regulating the cell cycle and transcription. Here, we describe a new trisubstituted pyrazolo[4,3-d]pyrimidine

Externí odkaz: https://doaj.org/article/ebadbe56eb674ba785bd3c09da68b0d5

Zobrazit plný text záznamu

Akademický článek

Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors

Autor: Monika Tomanová, Karolína Kozlanská, Radek Jorda, Lukáš Jedinák, Tereza Havlíková, Eva Řezníčková, Miroslav Peřina, Pavel Klener, Alexandra Dolníková, Petr Cankař, Vladimír Kryštof

Publikováno v: International Journal of Molecular Sciences, Vol 23, Iss 24, p 16169 (2022)

Therapy of FLT3-positive acute myeloid leukemia still remains complicated, despite the availability of newly approved kinase inhibitors. Various strategies to avoid the reduced efficacy of therapy have been explored, including the development of dual

Externí odkaz: https://doaj.org/article/116746868f804df5a2709a06c35a7b83

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2H-pyrazolo[4,3-c]pyridines

Autor: Beatričė Razmienė, Eva Řezníčková, Vaida Dambrauskienė, Radek Ostruszka, Martin Kubala, Asta Žukauskaitė, Vladimír Kryštof, Algirdas Šačkus, Eglė Arbačiauskienė

Publikováno v: Molecules, Vol 26, Iss 21, p 6747 (2021)

A library of 2,4,6,7-tetrasubstituted-2H-pyrazolo[4,3-c]pyridines was prepared from easily accessible 1-phenyl-3-(2-phenylethynyl)-1H-pyrazole-4-carbaldehyde via an iodine-mediated electrophilic cyclization of intermediate 4-(azidomethyl)-1-phenyl-3-

Externí odkaz: https://doaj.org/article/c1e5ffbbb6c3420e803de16af82fd513

Zobrazit plný text záznamu

Plný text ve formátu HTML

Supplementary Materials and Methods and Figure Legends from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

Autor: Wolfgang Mikulits, Vladimír Kryštof, Miroslav Strnad, Tomáš Gucký, Marek Zatloukal, Radek Jorda, Walter Berger, Walter Miklos, Hans Rotheneder, Thomas S. Weiss, Eva Řezníčková, Markus Grubinger, Christine Haider

PDF file, 82K.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cf26d254f2c41c95fa32ce8b973d975
https://doi.org/10.1158/1535-7163.22498959.v1

Zobrazit plný text záznamu

Supplementary Figure 3 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

PDF file, 228K, Proliferation kinetics of treated hepatoma cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dabad803bebde6f2c8a448dab86a2a3d
https://doi.org/10.1158/1535-7163.22498962

Zobrazit plný text záznamu

Supplementary Tables from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

PDF file, 227K, Suppl. table S1: IC50 values Suppl. table S2: Substrate specificity.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2955e3c3011effd76ec65a2c3d23da
https://doi.org/10.1158/1535-7163.22498956.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

PDF file, 97K, Chemical structure of BA-12 and BP-14.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3c0d4cf0125212de11412147b3a81d
https://doi.org/10.1158/1535-7163.22498968.v1

Zobrazit plný text záznamu

Supplementary Figure 2 from Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

PDF file, 169K, Viability of treated hepatoma cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::752cdce85ead9afc9caf05d4c0fe7dd3
https://doi.org/10.1158/1535-7163.22498965.v1

Zobrazit plný text záznamu

Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines

Autor: Hana Dostálová, Radek Jorda, Eva Řezníčková, Vladimír Kryštof

Small molecule Bruton’s tyrosine kinase (BTK) inhibitors have been developed for the treatment of various haemato-oncological diseases, and ibrutinib was approved as the first BTK inhibitors for anticancer therapy in 2013. Previous reports proved t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::380048841ad736572c23d6ccfdfaf0d8
https://doi.org/10.1101/2023.02.23.529815

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání